Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | SRC | P12931 | 5/20 | 1.00 |
| ▸ | EGFR | P00533 | 8/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17157132 | 1.00 | BTK (1.00) | BTKSRCEGFR | |
| SCHEMBL15691520 | 1.00 | BTK (1.00) | BTKSRCEGFR | |
| SCHEMBL15669970 | 0.92 | BTK (1.00) | BTKSRCEGFR | |
| SCHEMBL15669973 | 0.92 | BTK (1.00) | BTKSRCEGFR | |
| SCHEMBL17173963 | 0.92 | BTK (1.00) | BTKSRCEGFR | |
| SCHEMBL17173970 | 0.92 | BTK (1.00) | BTKSRCEGFR | |
| SCHEMBL15691524 | 0.92 | BTK (1.00) | BTKSRCEGFR | |
| SCHEMBL17157116 | 0.92 | BTK (1.00) | BTKSRCEGFR | |
| SCHEMBL15669964 | 0.91 | BTK (1.00) | BTKSRCEGFR | |
| SCHEMBL15669922 | 0.91 | BTK (1.00) | BTKSRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20170283393-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2914586-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | PFIZER (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2914586-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Pfizer Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014068527-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | BTK 1/4885SRC 7/4885EGFR 833/4885 |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | BTK 1/4885SRC 10/4885EGFR 653/4885 |
| US-20170283393-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | BTK 1/4885SRC 6/4885EGFR 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.